news

Padlock Therapeutics accelerates pipeline development through agreement with GSK

Posted: 29 May 2015 | Victoria White

Padlock Therapeutics has entered into an agreement to license intellectual property and a collection of assets targeted at PADs from GSK…

Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, has entered into an agreement to license intellectual property and a collection of assets targeted at protein-arginine deiminases (PADs) from GSK.

Padlock Therapeutics plans to use these assets to expand the breadth and depth of its proprietary chemistry portfolio in an effort to create fundamentally new treatments for autoimmune disease by targeting the PAD enzymes.

Clinical applications under evaluation at Padlock Therapeutics include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Padlock Therapeutics and GSK collaboration will expedite getting PAD-directed medicines to patients

Under the terms of the agreement, Padlock Therapeutics will receive exclusive rights to a package of assets including intellectual property, selected compounds in several chemical series, assays, data and crystal structures developed by GSK scientists. In return, GSK will receive an undisclosed equity grant and board observer rights.

“Since our founding just over a year ago, the Padlock team has achieved numerous research milestones as we build our PAD enzyme chemistry engine,” said Michael Gilman, Ph.D., Founder and Chief Executive Officer at Padlock Therapeutics. “We are thrilled to add GSK’s assets and know-how to our platform. We believe that the compounds, methods, and data obtained from GSK, combined with our own internal expertise and proprietary chemistry, create an industry leading R&D effort focused on the PAD enzymes and will expedite getting PAD-directed medicines to patients with serious autoimmune diseases.”

Related topics

Related conditions